PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Cited by (1,079)

Items 801–900 of 1,079

1. Tumor Heterogeneity in Colorectal Cancer: What Do We Know So Far?
   Xavier Sagaert, Arno Vanstapel, Sanne Verbeek · 2018 · Pathobiology
2. Emerging Multimodality Approaches to Treat Localized Esophageal Cancer
   Ronan Joseph Kelly · 2019 · Journal of the National Comprehensive Cancer Network
3. A comprehensive review and performance evaluation of bioinformatics tools for HLA class I peptide-binding prediction
   Shutao Mei, Fuyi Li, André Leier, Tatiana T. Marquez‐Lago, Kailin Giam, Nathan P. Croft, Tatsuya Akutsu, A. Ian Smith, Jian Li, Jamie Rossjohn et al. · 2019 · Briefings in Bioinformatics
4. Molecular pathology of Lynch syndrome
   Guia Cerretelli, Ann Ager, Mark Johan Arends, Ian M. Frayling · 2020 · The Journal of Pathology
5. Germline genetic contribution to the immune landscape of cancer
   Rosalyn W. Sayaman, Mohamad Saad, Vésteinn Thórsson, Donglei Hu, Wouter Hendrickx, Jessica P Roelands, Eduard Porta‐Pardo, Younes Mokrab, Farshad Farshidfar, Tomas Kirchhoff et al. · 2021 · Immunity
6. Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract
   Michael Lawrence Dougan · 2017 · Frontiers in Immunology
7. Autologous iPSC-Based Vaccines Elicit Anti-tumor Responses In Vivo
   Nigel G. Kooreman, Youngkyun Kim, Patricia E. de Almeida, Vittavat Termglinchan, Sebastian Diecke, Ning‐Yi Shao, Tzu-Tang Wei, Hyoju Yi, Devaveena Dey, Raman V. Nelakanti et al. · 2018 · Cell stem cell
8. Novel Approaches to Improve the Efficacy of Immuno-Radiotherapy
   Maxim Alekseevich Shevtsov, Hiro Sato, Gabriele Multhoff, Atsushi Shibata · 2019 · Frontiers in Oncology
9. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer
   Sandra Assoun, Nathalie Théou–Anton, Marina Nguenang, Aurélie Cazes, Claire J. Danel, Baptiste Abbar, Johan Pluvy, Valérie Gounant, Antoine Khalil, Céline Namour et al. · 2019 · Lung Cancer
10. Nivolumab Is Effective in Mismatch Repair–Deficient Noncolorectal Cancers: Results From Arm Z1D—A Subprotocol of the NCI-MATCH (EAY131) Study
    Nilofer Saba Azad, Robert J. Gray, Michael James Overman, Jonathan Daniel Schoenfeld, Edith Peterson Mitchell, James A. Zwiebel, Elad Sharon, HOWARD Z. STREICHER, Shuli Li, Lisa M. McShane et al. · 2019 · Journal of Clinical Oncology
11. Genomic profiling in renal cell carcinoma
    Nazlı Dizman, Errol James Philip, Sumanta Kumar Pal · 2020 · Nature Reviews Nephrology
12. Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta‐analysis
    Jessica Nell McAlpine, Derek S. Chiu, Remi A. Nout, David N. Church, Pascal Schmidt, Stéphanie Lam, Samuel C. Y. Leung, Stefania Bellone, Adele Wong, Sara Yvonne Brucker et al. · 2021 · Cancer
13. Mismatch Repair-Deficient Colorectal Cancer: Building on Checkpoint Blockade
    Zhaohui Jin, Frank A. Sinicrope · 2022 · Journal of Clinical Oncology
14. The Many Facets of Therapy Resistance and Tumor Recurrence in Glioblastoma
    Goenka, Anshika, Tiek, Deanna, Song, Xiao, Huang, Tianzhi, Hu, Bo, Cheng, Shi-Yuan · 2021 · Cells
15. Integrative analysis of exogenous, endogenous, tumour and immune factors for precision medicine
    Shuji Ogino, Jonathan Andrew Nowak, Tsuyoshi Hamada, Amanda I. Phipps, Ulrike Peters, Danny A. Milner, Edward L. Giovannucci, Reiko Nishihara, Marios Giannakis, Wendy S. Garrett et al. · 2018 · Gut
16. PD-L1-Mediated Immunosuppression in Glioblastoma Is Associated With the Infiltration and M2-Polarization of Tumor-Associated Macrophages
    Zhiyuan Zhu, Hongbo Zhang, Baodong Chen, Xing Liu, Shizhong Zhang, Zhitao Zong, Mengqi Gao · 2020 · Frontiers in Immunology
17. Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis
    Feng Wang, Ming-Ming He, Yi-Chen Yao, Xia Zhao, Zhi‐Qiang Wang, Ying Jin, Hui Luo, Jibin Li, Feng‐Hua Wang, Miao‐Zhen Qiu et al. · 2021 · Cell Reports Medicine
18. Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma
    Peter J. Bailey, David Kuang-Fu Chang, Marie‐Andrée Forget, Francis Anthony San Lucas, Hector A. Alvarez, Cara Haymaker, Chandrani Chattopadhyay, Sun-Hee Kim, Sühendan Ekmekçioglu, Elizabeth Ann Grimm et al. · 2016 · Scientific Reports
19. Advances in Cancer Immunotherapy in Solid Tumors
    Smitha Patiyil Menon, Sarah J. Shin, Grace Kho Dy · 2016 · Cancers
20. Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial
    Bastiaan G. Wortman, Tjalling Bosse, Remi A. Nout, Ludy C.H.W. Lutgens, Elzbieta M. van der Steen‐Banasik, Henrike G. Westerveld, H. van den Berg, Annerie Slot, Karin A.J. De Winter, Karen W. Verhoeven-Adema et al. · 2018 · Gynecologic Oncology
21. Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer
    Zhenyu Lin, Ming Cai, Peng Zhang, Gang Li, Tao Liu, Xin Li, Kailin Cai, Xiu Nie, Jing Wang, Junli Liu et al. · 2021 · Journal for ImmunoTherapy of Cancer
22. Aspirin promotes RSL3-induced ferroptosis by suppressing mTOR/SREBP-1/SCD1-mediated lipogenesis in PIK3CA-mutant colorectal cancer
    Hao Chen, Qinqin Qi, Nan Wu, Ying Wang, Qian Feng, Rong Jin, Lei Jiang · 2022 · Redox Biology
23. Translating cancer genomes and transcriptomes for precision oncology
    Sameek Roychowdhury, Arul M. Chinnaiyan · 2015 · CA A Cancer Journal for Clinicians
24. Genomic landscape of DNA repair genes in cancer
    Young Kwang Chae, Jonathan Forrest Anker, Benedito A. Carneiro, Sunandana Chandra, Jason Benjamin Kaplan, Aparna Kalyan, Cesar Augusto Santa-Maria, Leonidas C. Platanias, Francis Joseph Giles · 2016 · Oncotarget
25. Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities
    Goran Micevic, Nicholas Theodosakis, Marcus Bosenberg · 2017 · Clinical Epigenetics
26. Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer
    Heather L. Kinkead, Alexander C. Hopkins, Eric R. Lutz, Annie A. Wu, Mark M. Yarchoan, Kayla A. Cruz, Skylar Woolman, Teena Vithayathil, Laura Hix Glickman, Chudi O. Ndubaku et al. · 2018 · JCI Insight
27. Metastatic prostate cancer remains incurable, why?
    Liang Dong, Richard C. Zieren, Wei Xue, Theo M. de Reijke, Kenneth J. Pienta · 2018 · Asian journal of urology
28. Inflammation promotes resistance to immune checkpoint inhibitors in high microsatellite instability colorectal cancer
    Qiaoqi Sui, Xi Zhang, Chao Chen, Jinghua Tang, Jiehai Yu, Weihao Li, Kai Han, Jiang Wu, Leen Liao, Ling-Heng Kong et al. · 2022 · Nature Communications
29. Colorectal cancer: the facts in the case of the microbiota
    Clay, Slater L., Fonseca-Pereira, Diogo, Garrett, Wendy S. · 2022 · Journal of Clinical Investigation
30. Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches
    Aaron M. Udager, Ting‐yu Liu, Stephanie L. Skala, Martin J. Magers, Andrew S. McDaniel, Daniel Eidelberg Spratt, Felix Yi-Chung Feng, Javed Siddiqui, Xuhong Cao, Kristina L. Fields et al. · 2016 · Annals of Oncology
31. Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy
    Yoshio Nakamura, Shigehisa Kitano, Akira Takahashi, Arata Tsutsumida, Kenjiro Namikawa, Keiji Tanese, Takayuki Abe, Takeru Funakoshi, Noboru Yamamoto, Masayuki Amagai et al. · 2016 · Oncotarget
32. Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer
    Gillian Rae Vandekerkhove, Tilman Todenhöfer, Matti Annala, Werner Jan Struss, Amanda Wong, Kevin Beja, Elie J. Ritch, Sonal Brahmbhatt, Stanislav V. Volik, Jörg Hennenlotter et al. · 2017 · Clinical Cancer Research
33. Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity
    Valsamo Anagnostou, Mark M. Yarchoan, Aaron Richard Hansen, Hao Wang, Franco Verde, Elad Sharon, Deborah E. Collyar, Laura Q.M. Chow, Patrick M. Forde · 2017 · Clinical Cancer Research
34. Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF)
    Hendrik‐Tobias Arkenau, Juan Martín-Liberal, Emiliano Calvo, Nicolas Penel, Matthew Krebs, Roy S. Herbst, Richard A. Walgren, Ryan C. Widau, Gu Mi, Jin Jin et al. · 2018 · The Oncologist
35. Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma
    Celina Ang, Samuel Jacob Klempner, Siraj Mahamed Ali, Russell William Madison, Jeffrey S. Ross, Eric Allan Severson, David A. Fabrizio, Aaron Michael Goodman, Razelle Kurzrock, James H. Suh et al. · 2019 · Oncotarget
36. TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials
    Khalil Choucair, Susan M. Morand, Laura Stanbery, Gerald M. Edelman, Lance D. Dworkin, John J. Nemunaitis · 2020 · Cancer Gene Therapy
37. Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine
    Conway, Jake R., Kofman, Eric, Mo, Shirley S., Elmarakeby, Haitham, Van Allen, Eliezer · 2018 · Genome Medicine
38. Biomarkers associated with checkpoint inhibitors
    Guillaume Manson, J. Norwood, Aurélien Marabelle, Holbrook E K Kohrt, Roch Houot · 2016 · Annals of Oncology
39. Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers
    Muhammad Umair Mushtaq, Athanasios Papadas, Adam C. Pagenkopf, Evan Flietner, Zachary T. Morrow, Sibgha Gull Chaudhary, Fotis A. Asimakopoulos · 2018 · Journal for ImmunoTherapy of Cancer
40. Predicting Antigen Presentation—What Could We Learn From a Million Peptides?
    David Gfeller, Michal Bassani‐Sternberg · 2018 · Frontiers in Immunology
41. Relationship between MLH1 , PMS2 , MSH2 and MSH6 gene‐specific alterations and tumor mutational burden in 1057 microsatellite instability‐high solid tumors
    Mohamed E. Salem, Joseph Nicholas Bodor, Alberto Puccini, Joanne Xiu, Richard M. Goldberg, Axel F. Grothey, Wolfgang Michael Korn, Anthony Frank Shields, William Mills Worrilow, Edward S. Kim et al. · 2020 · International Journal of Cancer
42. Strategies for Increasing Pancreatic Tumor Immunogenicity
    Burles Avner Johnson, Mark M. Yarchoan, Valerie Lee, Daniel A. Laheru, Elizabeth M. Jaffee · 2017 · Clinical Cancer Research
43. Digestive System Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms
    Louis de Mestier, Jerome F. Cros, Cindy Neuzillet, Olivia Hentic, Axel Egal, Nelly Müller, Olivier Bouché, Guillaume Cadiot, Philippe B Ruszniewski, Anne Couvelard et al. · 2017 · Neuroendocrinology
44. A computational multiscale agent-based model for simulating spatio-temporal tumour immune response to PD1 and PDL1 inhibition
    Chang Gong, Oleg Milberg, Bing Wang, Paolo Vicini, Rajesh Narwal, Lorin K. Roskos, Aleksander S. Popel · 2017 · Journal of The Royal Society Interface
45. Heterogenous loss of mismatch repair (MMR) protein expression: a challenge for immunohistochemical interpretation and microsatellite instability (MSI) evaluation
    Aoife J McCarthy, José‐Mario Capo‐Chichi, Tara Spence, Sylvie Grenier, Tracy L. Stockley, Suzanne Kamel‐Reid, Stefano Serra, Peter J. B. Sabatini, Runjan Chetty · 2018 · The Journal of Pathology Clinical Research
46. Molecular Classification and Emerging Targeted Therapy in Endometrial Cancer
    Ting‐Tai Yen, Tian‐Li Wang, Amanda N. Fader, Ie‐Ming Shih, Stephanie L. Gaillard · 2019 · International Journal of Gynecological Pathology
47. The immune landscape and response to immune checkpoint blockade therapy in lymphoma
    Justin Paul Kline, James K. Godfrey, Stephen Maxted Ansell · 2019 · Blood
48. Cellular and gene signatures of tumor-infiltrating dendritic cells and natural-killer cells predict prognosis of neuroblastoma
    Ombretta Melaiu, Marco Chierici, Valeria Lucarini, Giuseppe Jurman, Libenzio Adrian Conti, Rita De Vito, Renata Boldrini, Loredana Cifaldi, Aurora Castellano, Cesare Furlanello et al. · 2020 · Nature Communications
49. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2020 for the Clinical Practice of Hereditary Colorectal Cancer
    Naohiro Tomita, Hideyuki Ishida, Kohji Tanakaya, Tatsuro Yamaguchi, Kensuke Kumamoto, Toshiaki Tanaka, Takao Hinoi, Yasuyuki Miyakura, Hirotoshi Hasegawa, Tetsuji Takayama et al. · 2021 · International Journal of Clinical Oncology
50. Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: Guideline From the College of American Pathologists in Collaboration With the Association for Molecular Pathology and Fight Colorectal Cancer
    Angela N. Bartley, Anne M. Mills, Eric Quentin Konnick, Michael James Overman, Christina B. Ventura, Lesley Souter, Carol Colasacco, Zsofia Kinga Stadler, Sarah E. Kerr, Brooke E. Howitt et al. · 2022 · Archives of Pathology & Laboratory Medicine
51. Landscape of Tumor Antigens in T Cell Immunotherapy
    Sadia Ilyas, James Chih‐Hsin Yang · 2015 · The Journal of Immunology
52. Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors
    Ludmila Danilova, Hao Wang, Joel Chaim Sunshine, Genevieve J. Kaunitz, Tricia R. Cottrell, Haiying Xu, Jessica Esandrio, Robert A. Anders, Leslie Cope, Drew M. Pardoll et al. · 2016 · Proceedings of the National Academy of Sciences
53. Adjuvant Chemotherapy for Stage II Colon Cancer: A Clinical Dilemma
    Joseph Kannarkatt, Joe P Joseph, Peter C. Kurniali, Anas Al-Janadi, Borys W. Hrinczenko · 2017 · Journal of Oncology Practice
54. Update on Tumor Neoantigens and Their Utility: Why It Is Good to Be Different
    Chung‐Han Lee, Roman Yelensky, Karin U. Jooss, Timothy An-thy Chan · 2018 · Trends in Immunology
55. Multi-level Proteomics Identifies CT45 as a Chemosensitivity Mediator and Immunotherapy Target in Ovarian Cancer
    Fabian Coscia, Ernst R. Lengyel, Jaikumar Duraiswamy, Bradley Ashcroft, Michal Bassani‐Sternberg, Michael Wierer, Alyssa Johnson, Kristen Wroblewski, ANTHONY G. MONTAG, S. Diane Yamada et al. · 2018 · Cell
56. Colorectal cancer occurrence and treatment based on changes in intestinal flora
    Huifang Si, Qing fan Yang, Hong‐Ming Hu, Chunsheng Ding, Huichao Wang, Xuhong Lin · 2020 · Seminars in Cancer Biology
57. Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities
    Xuan Zhang, Tao Wu, Xinyi Cai, Jianhua Dong, Cuifeng Xia, Yongchun Zhou, Rong Ding, Renfang Yang, Jing Tan, Lijuan Zhang et al. · 2022 · Frontiers in Immunology
58. Regression of Chemotherapy-Resistant Polymerase ϵ (POLE) Ultra-Mutated and MSH6 Hyper-Mutated Endometrial Tumors with Nivolumab
    Alessandro Davide Santin, Stefania Bellone, Natália Buza, Jungmin Choi, Peter E. Schwartz, Joseph Schlessinger, Richard P. Lifton · 2016 · Clinical Cancer Research
59. Deep learning in digital pathology image analysis: a survey
    Shujian Deng, Xin Zhang, Yan Wen, Eric Chang, Yubo Fan, Maode Lai, Yan Lei Xu · 2020 · Frontiers of Medicine
60. Effects of microsatellite instability on recurrence patterns and outcomes in colorectal cancers
    Chang Gon Kim, Joong Bae Ahn, Minkyu Jung, Seung‐Hoon Beom, Chan Kim, Joo Hoon Kim, Su Jin Heo, Hyung Soon Park, Jee Hung Kim, Nam Kyu Kim et al. · 2016 · British Journal of Cancer
61. Pancreatic Cancer Genomes: Implications for Clinical Management and Therapeutic Development
    Stephan B. Dreyer, David Kuang-Fu Chang, Peter J. Bailey, Andrew Victor Biankin · 2017 · Clinical Cancer Research
62. Immune Checkpoints as a Target for Colorectal Cancer Treatment
    Alessandro Passardi, Matteo Canale, Martina Valgiusti, Paola Ulivi · 2017 · International Journal of Molecular Sciences
63. PD-1 and cancer: molecular mechanisms and polymorphisms
    Arash Salmaninejad, Vahid Khoramshahi, Alireza Azani, Ehsan Soltaninejad, Saeed Aslani, Mohammad Reza Zamani, Masoud Zal, Abolfazl Nesaei, Sayed Mostafa Hosseini · 2017 · Immunogenetics
64. ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer
    Qiang Li, Alexis W. Damish, Zoë Frazier, David Liu, Elizaveta Reznichenko, Atanas Kamburov, Andrew Bell, HuiYong Zhao, Emmet Jordan, Sizhi Paul Gao et al. · 2018 · Clinical Cancer Research
65. Molecular Subtype Not Immune Response Drives Outcomes in Endometrial Carcinoma
    Aline Talhouk, Heather Derocher, Pascal Schmidt, Samuel C. Y. Leung, Katy Milne, C. Blake Gilks, Michael S. Anglesio, Brad H. Nelson, Jessica Nell McAlpine · 2019 · Clinical Cancer Research
66. Titin mutation associated with responsiveness to checkpoint blockades in solid tumors
    Qingzhu Jia, Jun Wang, Ning He, Ji He, Bo Zhu · 2019 · JCI Insight
67. Drugging the Cancers Addicted to DNA Repair
    Jac A. Nickoloff, Dennie V. Jones, Suk‐Hee Lee, Elizabeth A. Williamson, Robert Hromas · 2017 · JNCI Journal of the National Cancer Institute
68. Neoantigen prediction and computational perspectives towards clinical benefit: recommendations from the ESMO Precision Medicine Working Group
    Leticia De Mattos‐Arruda, Miguél Vázquez, Francesca Finotello, Rosalba Lepore, E. Porta, Jasreet Hundal, Pep Amengual-Rigo, Charlotte K.Y. Ng, Alfonso Valencia, Jorge Carrillo et al. · 2020 · Annals of Oncology
69. Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial
    Andrea J. Bullock, Benjamin L. Schlechter, Marwan Fakih, Apostolia Maria Tsimberidou, Joseph Elan Grossman, Michael S. Gordon, Breelyn Ann Wilky, Agustin Pimentel, Daruka Mahadevan, Ani Sarkis Balmanoukian et al. · 2024 · Nature Medicine
70. MSH2 Loss in Primary Prostate Cancer
    Liana B. Guedes, Emmanuel S. Antonarakis, Michael Thomas Schweizer, Nooshin Mirkheshti, Fawaz Almutairi, Jong Chul Park, Stephanie A. Glavaris, Jessica L Hicks, Mario A. Eisenberger, Angelo Michael De Marzo et al. · 2017 · Clinical Cancer Research
71. Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer
    Michael C. Haffner, Güneş Güner, Diana Taheri, George Jabboure Netto, Doreen N. Palsgrove, Qizhi Zheng, Liana B. Guedes, Kunhwa Kim, Harrison Kwei Tsai, David Esopi et al. · 2018 · American Journal Of Pathology
72. Detection of Mismatch Repair Deficiency and Microsatellite Instability in Colorectal Adenocarcinoma by Targeted Next-Generation Sequencing
    Jonathan Andrew Nowak, Matthew B.B. Yurgelun, Jacqueline L. Bruce, Vanesa Rojas‐Rudilla, Dimity L. Hall, Priyanka Shivdasani, Elizabeth P. Garcia, Agoston T. Agoston, Amitabh Srivastava, Shuji Ogino et al. · 2016 · Journal of Molecular Diagnostics
73. Intrinsic Resistance of Solid Tumors to Immune Checkpoint Blockade Therapy
    Xianda Zhao, Subbaya Subramanian · 2017 · Cancer Research
74. Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy
    Chunyan Yue, Yubo Jiang, Ping Li, Yuehua Wang, Jian Xue, Nannan Li, Da Li, Ruina Wang, Yongjun Dang, Zhiyuan Hu et al. · 2018 · OncoImmunology
75. Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency
    Anirban Das, Sumedha Sudhaman, Daniel A. Morgenstern, Ailish C. Coblentz, Jiil Chung, Simone C. Stone, Noor Said Alsafwani, Zhihui Amy Liu, Ola Abu Al Karsaneh, Shirin Soleimani et al. · 2022 · Nature Medicine
76. Dietary Lactobacillus -Derived Exopolysaccharide Enhances Immune-Checkpoint Blockade Therapy
    Hirotaka Kawanabe-Matsuda, Kazuyoshi Takeda, Marie Nakamura, Seiya Makino, Takahiro Karasaki, Kazuhiro Kakimi, Megumi Nishimukai, Tatsukuni Ohno, Jumpei Omi, Kuniyuki Kano et al. · 2022 · Cancer Discovery
77. Immune checkpoint inhibition in ovarian cancer
    Junzo Hamanishi, Masaki Mandai, Ikuo Konishi · 2016 · International Immunology
78. Cancer immune contexture and immunotherapy
    Étienne Becht, Nicolás A. Giraldo, Marie‐Caroline Dieu‐Nosjean, Catherine Sautès‐Fridman, Wolf H. Fridman · 2015 · Current Opinion in Immunology
79. Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma
    Faiz Gani, Neeraja Nagarajan, Yuhree Kim, Qingfeng Zhu, Lan Luan, Feriyl Bhaijee, Robert A. Anders, Timothy Michael Pawlik · 2016 · Annals of Surgical Oncology
80. Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy
    Édouard Auclin, Aziz Zaanan, Déwi Vernerey, Richard Douard, Claire Gallois, Pierre Laurent‐Puig, Franck Bonnetain, Julien Taı̈eb · 2017 · Annals of Oncology
81. Immunotherapy for Brain Tumors
    John Howard Sampson, Marcela Valderrama Maus, Carl H. June · 2017 · Journal of Clinical Oncology
82. Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma
    Markus W. Loeffler, Christopher Mohr, Leon Bichmann, Lena Katharina Freudenmann, Mathias Walzer, Christopher Schroeder, Nico Trautwein, Franz J. Hilke, Raphael S. Zinser, Lena Mühlenbruch et al. · 2019 · Genome Medicine
83. A genomic view of short tandem repeats
    Melissa Gymrek · 2017 · Current Opinion in Genetics & Development
84. KRAS Mutation and Consensus Molecular Subtypes 2 and 3 Are Independently Associated with Reduced Immune Infiltration and Reactivity in Colorectal Cancer
    Neeraj Lal, Brian S. White, Ghaleb Goussous, Oliver J. Pickles, Mike J. Mason, Andrew David Beggs, Philippe Tanière, Benjamin E. Willcox, Justin Guinney, Gary Middleton · 2017 · Clinical Cancer Research
85. Systemic treatment of advanced esophageal squamous cell carcinoma: chemotherapy, molecular-targeting therapy and immunotherapy
    Hidekazu Hirano, Ken Kato · 2019 · Japanese Journal of Clinical Oncology
86. Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytes
    Alena Gros, Eric Tran, Maria R. Parkhurst, Sadia Ilyas, Anna Pasetto, Eric M. Groh, Paul F. Robbins, Rami Yossef, Andrea García-Garijo, Carlos Alberto Fajardo et al. · 2019 · Journal of Clinical Investigation
87. Mechanisms of T-Cell Exhaustion in Pancreatic Cancer
    Didem Saka, Muazzez Gökalp, Betül Piyade, Nedim Can Çevik, Elif Arik Sever, Derya Unutmaz, Guralp Onur Ceyhan, İhsan Ekin Demir, Hande Asimgil · 2020 · Cancers
88. Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1
    Zi Yin, Min Yu, Tingting Ma, Chuanzhao Zhang, Shanzhou� Huang, Mohammad Reza Karimzadeh, Amir Abbas Momtazi‐Borojeni, Sheng Chen · 2021 · Journal for ImmunoTherapy of Cancer
89. Colorectal cancer immunotherapy-Recent progress and future directions
    Wen Zhao, Lujia Jin, Peng Chen, Dingchang Li, Wenxing Gao, Guanglong Dong · 2022 · Cancer Letters
90. Transforming Cancer Prevention through Precision Medicine and Immune-oncology
    Thomas W. Kensler, Avrum E. Spira, Judy Ellen Garber, Eva M. Szabo, J. Jack Lee, Zigang Dong, Andrew J. Dannenberg, William N. Hait, Elizabeth Helen Blackburn, Nancy E. Davidson et al. · 2016 · Cancer Prevention Research
91. Immunotherapy in ovarian, endometrial and cervical cancer: State of the art and future perspectives
    Jole Ventriglia, Immacolata Paciolla, Carmela Pisano, Sabrina Chiara Cecere, Marilena Di Napoli, Rosa Tambaro, Daniela Califano, Simona Losito, Giosuè Scognamiglio, Sergio Venanzio Setola et al. · 2017 · Cancer Treatment Reviews
92. Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies
    Michael Collins, Jean‐Marie Michot, F.X. Danlos, Charlotte Mussini, Émilie Soularue, Christine Mateus, Delphine Loirat, Anthony Buisson, Isabelle Rosa, Olivier Lambotte et al. · 2017 · Annals of Oncology
93. Immunotherapy for osteosarcoma: Where do we go from here?
    Mary Frances Wedekind, Lars M. Wagner, Timothy P. Cripe · 2018 · Pediatric Blood & Cancer
94. Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
    Jong Yeob Kim, Andreas Kronbichler, Michael Eisenhut, Sung Hwi Hong, Hans J. van der Vliet, Jeonghyun Kang, Jae Il Shin, Gabriele Gamerith · 2019 · Cancers
95. Therapeutic Implications of Germline Testing in Patients With Advanced Cancers
    Zsofia Kinga Stadler, Anna Maio, Debyani Chakravarty, Yelena M. Kemel, Margaret R. Sheehan, Erin E. Salo‐Mullen, Kaitlyn A. Tkachuk, Christopher John Fong, Bastien Nguyen, Amanda Erakky et al. · 2021 · Journal of Clinical Oncology
96. Neoantigen-specific CD4+ T cells in human melanoma have diverse differentiation states and correlate with CD8+ T cell, macrophage, and B cell function
    Joshua R. Veatch, Sylvia M. Lee, Carolyn Shasha, Naina Singhi, Julia L. Szeto, Ata S. Moshiri, Teresa S. Kim, Kimberly S. Smythe, Paul Kong, Matthew Fitzgibbon et al. · 2022 · Cancer Cell
97. Expansion of T memory stem cells with superior anti-tumor immunity by Urolithin A-induced mitophagy
    Dominic Denk, Valentina Petrocelli, Claire Conche, Moritz Wolfgang Drachsler, Paul K. Ziegler, Angela Braun, Alena Kress, Adele M. Nicolas, Kathleen Mohs, Christoph Becker et al. · 2022 · Immunity
98. Molecular subtypes of colorectal cancer: An emerging therapeutic opportunity for personalized medicine
    Manish Pratap Singh, S. Rai, Ashutosh Pandey, Nand Kumar Singh, Sameer Srivastava · 2019 · Genes & Diseases
99. Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II Trial
    Sophie Cousin, Coralie Cantarel, Jean‐Philippe Guégan, Carlos Gomez‐Roca, Jean‐Philippe Metges, Antoine Adenis, Simon Pernot, Carine A. Bellera, Michèle Kind, Céline Auzanneau et al. · 2021 · Clinical Cancer Research
100. Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient, locally advanced rectal cancer: an open-label, single-centre phase 2 study
     Gong Chen, Ying Jin, Wen‐Long Guan, Rongxin Zhang, Weiwei Xiao, Peiqiang Cai, Min Liu, Junzhong Lin, Fulong Wang, Cong Li et al. · 2023 · The Lancet. Gastroenterology & hepatology